{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T03:52:59Z","timestamp":1767153179318,"version":"build-2238731810"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,3,25]],"date-time":"2021-03-25T00:00:00Z","timestamp":1616630400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,3,25]],"date-time":"2021-03-25T00:00:00Z","timestamp":1616630400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Vaincre La Mucoviscidose","award":["RF20180502264"],"award-info":[{"award-number":["RF20180502264"]}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"crossref","award":["ANR-13-BSV1-0019-02"],"award-info":[{"award-number":["ANR-13-BSV1-0019-02"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"crossref"}]},{"name":"GENCI-[CINES]","award":["2017-A0020707206, 2018-A0040707206, 2019-A006707206"],"award-info":[{"award-number":["2017-A0020707206, 2018-A0040707206, 2019-A006707206"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>C407 is a compound that corrects the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) protein carrying the p.Phe508del (F508del) mutation. We investigated the corrector effect of c407 and its derivatives on F508del-CFTR protein. Molecular docking and dynamics simulations combined with site-directed mutagenesis suggested that c407 stabilizes the F508del-Nucleotide Binding Domain 1 (NBD1) during the co-translational folding process by occupying the position of the p.Phe1068 side chain located at the fourth intracellular loop (ICL4). After CFTR domains assembly, c407 occupies the position of the missing p.Phe508 side chain. C407 alone or in combination with the F508del-CFTR corrector VX-809, increased CFTR activity in cell lines but not in primary respiratory cells carrying the F508del mutation. A structure-based approach resulted in the synthesis of an extended c407 analog G1, designed to improve the interaction with ICL4. G1 significantly increased CFTR activity and response to VX-809 in primary nasal cells of F508del homozygous patients. Our data demonstrate that in-silico optimized c407 derivative G1 acts by a mechanism different from the reference VX-809 corrector and provide insights into its possible molecular mode of action. These results pave the way for novel strategies aiming to optimize the flawed ICL4\u2013NBD1 interface.<\/jats:p>","DOI":"10.1038\/s41598-021-83240-x","type":"journal-article","created":{"date-parts":[[2021,3,25]],"date-time":"2021-03-25T07:06:58Z","timestamp":1616656018000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["New insights into structure and function of bis-phosphinic acid derivatives and implications for CFTR modulation"],"prefix":"10.1038","volume":"11","author":[{"given":"Sara","family":"Bitam","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmad","family":"Elbahnsi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geordie","family":"Creste","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iwona","family":"Pranke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benoit","family":"Chevalier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farouk","family":"Berhal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brice","family":"Hoffmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathalie","family":"Servel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nesrine","family":"Baatalah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danielle","family":"Tondelier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aurelie","family":"Hatton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christelle","family":"Moquereau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M\u00e9lanie","family":"Faria Da Cunha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Pastor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agathe","family":"Lepissier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandre","family":"Hinzpeter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Paul","family":"Mornon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guillaume","family":"Prestat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aleksander","family":"Edelman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Callebaut","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Gravier-Pelletier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Sermet-Gaudelus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,3,25]]},"reference":[{"key":"83240_CR1","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1016\/S0140-6736(16)00576-6","volume":"388","author":"JS Elborn","year":"2016","unstructured":"Elborn, J. S. Cystic fibrosis. Lancet 388, 2519\u20132531 (2016).","journal-title":"Lancet"},{"key":"83240_CR2","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/nature04712","volume":"440","author":"P Vergani","year":"2006","unstructured":"Vergani, P., Csan\u00e1dy, L. & Gadsby, D. C. The ABC protein turned chloride channel whose failure causes cystic fibrosis. Nature 440, 477\u2013478 (2006).","journal-title":"Nature"},{"key":"83240_CR3","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1126\/science.2475911","volume":"245","author":"JR Riordan","year":"1989","unstructured":"Riordan, J. R. et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 245, 1066\u20131073 (1989).","journal-title":"Science"},{"key":"83240_CR4","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.cell.2011.11.023","volume":"148","author":"JL Mendoza","year":"2012","unstructured":"Mendoza, J. L. et al. Requirements for efficient correction of DF508 CFTR revealed by analyses of evolved sequences. Cell 148, 164\u2013174 (2012).","journal-title":"Cell"},{"key":"83240_CR5","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1002\/pro.479","volume":"19","author":"I Protasevich","year":"2010","unstructured":"Protasevich, I. et al. Thermal unfolding studies show the disease causing F508del mutation in CFTR thermodynamically destabilizes nucleotide-binding domain 1. Protein Sci. 19, 1917\u20131931 (2010).","journal-title":"Protein Sci."},{"key":"83240_CR6","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.cell.2011.11.024","volume":"148","author":"WM Rabeh","year":"2012","unstructured":"Rabeh, W. M. et al. Correction of both NBD1 energetics and domain interface is required to restore \u0394F508 CFTR folding and function. Cell 148, 150\u2013163 (2012).","journal-title":"Cell"},{"key":"83240_CR7","doi-asserted-by":"publisher","first-page":"35825","DOI":"10.1074\/jbc.M110.131623","volume":"285","author":"PH Thibodeau","year":"2010","unstructured":"Thibodeau, P. H. et al. The cystic fibrosis-causing mutation deltaF508 affects multiple steps in cystic fibrosis transmembrane conductance regulator biogenesis. J. Biol. Chem. 285, 35825\u201335835 (2010).","journal-title":"J. Biol. Chem."},{"key":"83240_CR8","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1038\/nchembio.1253","volume":"9","author":"T Okiyoneda","year":"2013","unstructured":"Okiyoneda, T. et al. Mechanism-based corrector combination restores DF508-CFTR folding and function. Nat. Chem. Biol. 9, 444\u2013454 (2013).","journal-title":"Nat. Chem. Biol."},{"key":"83240_CR9","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1091\/mbc.e14-04-0935","volume":"27","author":"G Veit","year":"2016","unstructured":"Veit, G. et al. From CFTR biology toward combinatorial pharmacotherapy: expanded classification of cystic fibrosis mutations. Mol. Biol. Cell 27, 424\u2013433 (2016).","journal-title":"Mol. Biol. Cell"},{"key":"83240_CR10","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.biocel.2014.03.020","volume":"52","author":"IM Pranke","year":"2014","unstructured":"Pranke, I. M. & Sermet-Gaudelus, I. Biosynthesis of cystic fibrosis transmembrane conductance regulator. Int. J. Biochem. Cell Biol. 52, 26\u201338 (2014).","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"83240_CR11","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1016\/S0140-6736(09)60327-5","volume":"378","author":"BP O'Sullivan","year":"2009","unstructured":"O\u2019Sullivan, B. P. & Freedman, S. D. Cystic fibrosis. Lancet 378, 1891\u20131904 (2009).","journal-title":"Lancet"},{"key":"83240_CR12","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1056\/NEJMoa1105185","volume":"365","author":"BW Ramsey","year":"2011","unstructured":"Ramsey, B. W. et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N. Engl. J. Med. 365, 1663\u20131672 (2011).","journal-title":"N. Engl. J. Med."},{"key":"83240_CR13","doi-asserted-by":"publisher","first-page":"18843","DOI":"10.1073\/pnas.1105787108","volume":"108","author":"F Van Goor","year":"2011","unstructured":"Van Goor, F. et al. Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809. Proc. Natl. Acad. Sci. U.S.A. 108, 18843\u201318848 (2011).","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"83240_CR14","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1056\/NEJMoa1807120","volume":"379","author":"D Keating","year":"2018","unstructured":"Keating, D. et al. VX-445-tezacaftor-ivacaftor in patients with cystic fibrosis and one or two Phe508del alleles. N. Engl. J. Med. 379, 1612\u20131620 (2018).","journal-title":"N. Engl. J. Med."},{"key":"83240_CR15","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","volume":"381","author":"PG Middleton","year":"2019","unstructured":"Middleton, P. G. et al. Elexacaftor\u2013tezacaftor\u2013ivacaftor for cystic fibrosis with a single Phe508del allele. N. Engl. J. Med. 381, 1809\u20131819 (2019).","journal-title":"N. Engl. J. Med."},{"key":"83240_CR16","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1038\/s41591-018-0200-x","volume":"24","author":"G Veit","year":"2018","unstructured":"Veit, G. et al. Structure-guided combination therapy to potently improve the function of mutant CFTRs. Nat. Med. 24, 1732\u20131742 (2018).","journal-title":"Nat. Med."},{"key":"83240_CR17","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1002\/emmm.201302699","volume":"5","author":"N Odolczyk","year":"2013","unstructured":"Odolczyk, N. et al. Discovery of novel potent \u0394F508-CFTR correctors that target the nucleotide binding domain. EMBO Mol. Med. 5, 1484\u20131501 (2013).","journal-title":"EMBO Mol. Med."},{"key":"83240_CR18","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.jcf.2007.11.008","volume":"7","author":"G Wieczorek","year":"2008","unstructured":"Wieczorek, G. & Zielenkiewicz, P. DeltaF508 mutation increases conformational flexibility of CFTR protein. J. Cyst. Fibros. 7, 295\u2013300 (2008).","journal-title":"J. Cyst. Fibros."},{"key":"83240_CR19","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1007\/s00018-014-1749-2","volume":"72","author":"J-P Mornon","year":"2015","unstructured":"Mornon, J.-P., Hoffmann, B., Jonic, S., Lehn, P. & Callebaut, I. Full-open and closed CFTR channels, with lateral tunnels from the cytoplasm and an alternative position of the F508 region, as revealed by molecular dynamics. Cell Mol. Life Sci. 72, 1377\u20131403 (2015).","journal-title":"Cell Mol. Life Sci."},{"key":"83240_CR20","doi-asserted-by":"publisher","first-page":"12757","DOI":"10.1073\/pnas.1815287115","volume":"115","author":"Z Zhang","year":"2018","unstructured":"Zhang, Z., Liu, F. & Chen, J. Molecular structure of the ATP-bound, phosphorylated human CFTR. Proc. Natl. Acad. Sci. U.S.A. 115, 12757\u201312762 (2018).","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"83240_CR21","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1074\/jbc.M410968200","volume":"280","author":"HA Lewis","year":"2005","unstructured":"Lewis, H. A. et al. Impact of the deltaF508 mutation in first nucleotide-binding domain of human cystic fibrosis transmembrane conductance regulator on domain folding and structure. J. Biol. Chem. 280, 1346\u20131353 (2005).","journal-title":"J. Biol. Chem."},{"key":"83240_CR22","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.molmed.2011.10.003","volume":"18","author":"GL Lukacs","year":"2012","unstructured":"Lukacs, G. L. & Verkman, A. S. CFTR: folding, misfolding and correcting the DeltaF508 conformational defect. Trends Mol. Med. 18, 81\u201391 (2012).","journal-title":"Trends Mol. Med."},{"key":"83240_CR23","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.jmb.2012.03.001","volume":"419","author":"AA Aleksandrov","year":"2012","unstructured":"Aleksandrov, A. A. et al. Allosteric modulation balances thermodynamic stability and restores function of DF508 CFTR. J. Mol. Biol. 419, 41\u201360 (2012).","journal-title":"J. Mol. Biol."},{"key":"83240_CR24","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.jmb.2014.07.026","volume":"427","author":"L He","year":"2015","unstructured":"He, L. et al. Restoration of NBD1 thermal stability is necessary and sufficient to correct DF508 CFTR folding and assembly. J. Mol. Biol. 427, 106\u2013120 (2015).","journal-title":"J. Mol. Biol."},{"key":"83240_CR25","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.chembiol.2007.11.012","volume":"15","author":"LS Pissarra","year":"2008","unstructured":"Pissarra, L. S. et al. Solubilizing mutations used to crystallize one CFTR domain attenuate the trafficking and channel defects caused by the major cystic fibrosis mutation. Chem. Biol. 15, 62\u201369 (2008).","journal-title":"Chem. Biol."},{"key":"83240_CR26","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1002\/pro.2821","volume":"25","author":"JD Hall","year":"2016","unstructured":"Hall, J. D. et al. Binding screen for cystic fibrosis transmembrane conductance regulator correctors finds new chemical matter and yields insights into cystic fibrosis therapeutic strategy. Protein Sci. 25, 360\u2013373 (2016).","journal-title":"Protein Sci."},{"key":"83240_CR27","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1096\/fj.12-216119","volume":"27","author":"L He","year":"2013","unstructured":"He, L. et al. Correctors of \u0394F508 CFTR restore global conformational maturation without thermally stabilizing the mutant protein. FASEB J. 27, 536\u2013545 (2013).","journal-title":"FASEB J."},{"key":"83240_CR28","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/j.chembiol.2013.06.004","volume":"20","author":"CM Farinha","year":"2013","unstructured":"Farinha, C. M. et al. Revertants, low temperature, and correctors reveal the mechanism of F508del-CFTR rescue by VX-809 and suggest multiple agents for full correction. Chem. Biol. 20, 943\u2013955 (2013).","journal-title":"Chem. Biol."},{"key":"83240_CR29","doi-asserted-by":"publisher","first-page":"3829","DOI":"10.1007\/s00018-018-2835-7","volume":"75","author":"B Hoffmann","year":"2018","unstructured":"Hoffmann, B. et al. Combining theoretical and experimental data to decipher CFTR 3D structures and functions. Cell Mol. Life Sci. 75, 3829\u20133855 (2018).","journal-title":"Cell Mol. Life Sci."},{"key":"83240_CR30","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1124\/mol.117.108373","volume":"92","author":"RP Hudson","year":"2017","unstructured":"Hudson, R. P. et al. Direct binding of the corrector VX-809 to human CFTR NBD1: Evidence of an allosteric coupling between the binding site and the NBD1:CL4 interface. Mol. Pharmacol. 92, 124\u2013135 (2017).","journal-title":"Mol. Pharmacol."},{"key":"83240_CR31","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1124\/mol.118.111799","volume":"93","author":"O Laselva","year":"2018","unstructured":"Laselva, O., Molinski, S., Casavola, V. & Bear, C. E. Correctors of the major cystic fibrosis mutant interact through membrane-spanning domains. Mol. Pharmacol. 93, 612\u2013618 (2018).","journal-title":"Mol. Pharmacol."},{"key":"83240_CR32","doi-asserted-by":"publisher","first-page":"3016","DOI":"10.1091\/mbc.e13-05-0240","volume":"24","author":"HY Ren","year":"2013","unstructured":"Ren, H. Y. et al. VX-809 corrects folding defects in cystic fibrosis transmembrane conductance regulator protein through action on membrane-spanning domain 1. Mol Biol Cell 24, 3016\u20133024 (2013).","journal-title":"Mol Biol Cell"},{"key":"83240_CR33","doi-asserted-by":"publisher","first-page":"218","DOI":"10.12688\/f1000research.6683.2","volume":"4","author":"S Bitam","year":"2015","unstructured":"Bitam, S. et al. An unexpected effect of TNF-\u03b1 on F508del-CFTR maturation and function. F1000Res 4, 218 (2015).","journal-title":"F1000Res"},{"key":"83240_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-017-07504-1","volume":"7","author":"IM Pranke","year":"2017","unstructured":"Pranke, I. M. et al. Correction of CFTR function in nasal epithelial cells from cystic fibrosis patients predicts improvement of respiratory function by CFTR modulators. Sci. Rep. 7, 1\u201311 (2017).","journal-title":"Sci. Rep."},{"key":"83240_CR35","doi-asserted-by":"publisher","first-page":"2714","DOI":"10.1002\/elps.1150181505","volume":"18","author":"N Guex","year":"1997","unstructured":"Guex, N. & Peitsch, M. C. SWISS-MODEL\u00a0and the Swiss-PdbViewer: An environment for comparative protein modeling. Electrophoresis 18, 2714\u20132723 (1997).","journal-title":"Electrophoresis"},{"key":"83240_CR36","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1021\/jm0306430","volume":"47","author":"RA Friesner","year":"2004","unstructured":"Friesner, R. A. et al. Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J. Med. Chem. 47, 1739\u20131749 (2004).","journal-title":"J. Med. Chem."},{"key":"83240_CR37","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1021\/ct200723y","volume":"8","author":"K Hart","year":"2012","unstructured":"Hart, K. et al. Optimization of the CHARMM additive force field for DNA: Improved treatment of the BI\/BII conformational equilibrium. J. Chem. Theory Comput. 8, 348\u2013362 (2012).","journal-title":"J. Chem. Theory Comput."},{"key":"83240_CR38","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1002\/jcc.20945","volume":"29","author":"S Jo","year":"2008","unstructured":"Jo, S., Kim, T., Iyer, V. G. & Im, W. CHARMM-GUI: a web-based graphical user interface for CHARMM. J. Comput. Chem. 29, 1859\u20131865 (2008).","journal-title":"J. Comput. Chem."},{"key":"83240_CR39","doi-asserted-by":"publisher","first-page":"7830","DOI":"10.1021\/jp101759q","volume":"114","author":"JB Klauda","year":"2010","unstructured":"Klauda, J. B. et al. Update of the CHARMM all-atom additive force field for lipids: validation on six lipid types. J. Phys. Chem. B 114, 7830\u20137843 (2010).","journal-title":"J. Phys. Chem. B"},{"key":"83240_CR40","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1002\/jcc.23702","volume":"35","author":"EL Wu","year":"2014","unstructured":"Wu, E. L. et al. CHARMM-GUI membrane builder toward realistic biological membrane simulations. J. Comput. Chem. 35, 1997\u20132004 (2014).","journal-title":"J. Comput. Chem."},{"key":"83240_CR41","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1021\/acs.jctc.5b00935","volume":"12","author":"J Lee","year":"2016","unstructured":"Lee, J. et al. CHARMM-GUI input generator for NAMD, GROMACS, AMBER, OpenMM, and CHARMM\/OpenMM simulations using the CHARMM36 additive force field. J. Chem. Theory Comput. 12, 405\u2013413 (2016).","journal-title":"J. Chem. Theory Comput."},{"key":"83240_CR42","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/0263-7855(96)00018-5","volume":"14","author":"W Humphrey","year":"1996","unstructured":"Humphrey, W., Dalke, A. & Schulten, K. VMD\u2014visual molecular dynamics. J. Mol. Graph. 14, 33\u201338 (1996).","journal-title":"J. Mol. Graph."},{"key":"83240_CR43","doi-asserted-by":"publisher","first-page":"3314","DOI":"10.1021\/ct300418h","volume":"8","author":"BR Miller","year":"2012","unstructured":"Miller, B. R. et al. MMPBSA.py: an efficient program for end-state free energy calculations. J. Chem. Theory Comput. 8, 3314\u20133321 (2012).","journal-title":"J. Chem. Theory Comput."},{"key":"83240_CR44","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1021\/ci9004892","volume":"50","author":"J Esque","year":"2010","unstructured":"Esque, J., Oguey, C. & de Brevern, A. G. A novel evaluation of residue and protein volumes by means of Laguerre tessellation. J. Chem. Inf. Model. 50, 947\u2013960 (2010).","journal-title":"J. Chem. Inf. Model."},{"key":"83240_CR45","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1021\/ci100195t","volume":"51","author":"J Esque","year":"2011","unstructured":"Esque, J., Oguey, C. & de Brevern, A. G. Comparative analysis of threshold and tessellation methods for determining protein contacts. J. Chem. Inf. Model. 51, 493\u2013507 (2011).","journal-title":"J. Chem. Inf. Model."},{"key":"83240_CR46","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1021\/acs.jctc.7b00936","volume":"14","author":"A Elbahnsi","year":"2018","unstructured":"Elbahnsi, A., Retureau, R., Baaden, M., Hartmann, B. & Oguey, C. Holding the nucleosome together: a quantitative description of the DNA-histone interface in solution. J. Chem. Theory Comput. 14, 1045\u20131058 (2018).","journal-title":"J. Chem. Theory Comput."},{"key":"83240_CR47","doi-asserted-by":"publisher","first-page":"7193","DOI":"10.1039\/C5OB00707K","volume":"13","author":"MJ Fer","year":"2015","unstructured":"Fer, M. J. et al. 5\u2032-Methylene-triazole-substituted-aminoribosyl uridines as MraY inhibitors: synthesis, biological evaluation and molecular modeling. Org. Biomol. Chem. 13, 7193\u20137222 (2015).","journal-title":"Org. Biomol. Chem."}],"updated-by":[{"DOI":"10.1038\/s41598-021-98301-4","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,9,15]],"date-time":"2021-09-15T00:00:00Z","timestamp":1631664000000}}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-83240-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-83240-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-83240-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,29]],"date-time":"2023-01-29T23:45:56Z","timestamp":1675035956000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-83240-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,25]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["83240"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-83240-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,25]]},"assertion":[{"value":"15 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2021","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41598-021-98301-4","URL":"https:\/\/doi.org\/10.1038\/s41598-021-98301-4","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"SB, AE, CG, IP, \u00a8BC, FB, BH, NS, DT, AH, CM, MFDC, AL, AHi, JPM, GP, AE, IC, CGP, do not declare any potential financial and non-financial competing interest. ISG declares following fundings from Vertex Pharmaceuticals: Innovation Award funding program 2016 and 2017. She was PI in clinical trials from Vertex Pharmaceuticals and took part to scientific advisory boards organized by Vertex Pharmaceuticals, Eloxx and Proteostasis.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6842"}}